|
gptkbp:instanceOf
|
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01XE25
|
|
gptkbp:brand
|
gptkb:Mekinist
|
|
gptkbp:CASNumber
|
871700-17-3
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
|
|
gptkbp:chemicalFormula
|
C26H23FIN5O4
|
|
gptkbp:combinationTherapy
|
gptkb:dabrafenib
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
4.5 days
|
|
gptkbp:indication
|
BRAF V600E or V600K mutation-positive cancers
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:MEK_inhibitor
|
|
gptkbp:metabolism
|
non-CYP mediated
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
hypertension
rash
cardiac dysfunction
|
|
gptkbp:target
|
gptkb:MEK1
gptkb:MEK2
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:anaplastic_thyroid_cancer
gptkb:melanoma
|
|
gptkbp:bfsParent
|
gptkb:MEK_inhibitors
gptkb:dabrafenib
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trametinib
|